Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alana Nguyen
Institutions:
NewYork–Presbyterian Hospital,
Cornell University,
Weill Cornell Medicine,
Weill Cornell Medical Center
Observed institutions:
NewYork–Presbyterian Hospital,
Cornell University,
Weill Cornell Medicine,
Weill Cornell Medical Center,
San Jose State University
ORCID:
0000-0002-7316-073X
Observed ORCID:
0000-0002-7316-073X
OpenAlex ID:
A5010833419
Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
·
Clinical Cancer Research
·
1
Inhibition of Innate Lymphoid Cell Activation by Interleukin-23 Secreting Dendritic Cells During Bordetella pertussis Infections in Mice
2017
·
Daniel Rebelo Santos
, Alana Nguyen
, et al.
·
The Journal of Immunology
·
1
Supplementary Figure S7 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 4 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S13 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S9 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S7 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S5 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S12 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Table 1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S6 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 5 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S14 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Data from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S10 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S4 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Show more works
View as search
Works count:
34
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type